Pingfu Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Pingfu Feng has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Yufen Hu
Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA
5 shared publicationsAfaf A. Akladious
Louis Stokes Cleveland DVA Medical Center, Cleveland, OH, USA
2 shared publicationsAfaf Akladious
Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA
2 shared publicationsDrina Vurbic
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA
2 shared publicationsKingman P. Strohl
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA; Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA
2 shared publicationsYang Guo
Louis Stokes Cleveland VA Medical Center, Research Sec, Rm: K217, 10701 East BLVD, Cleveland, Ohio 44106, USA
2 shared publications
Latest Publications
- Open Access
- 14 February 2018
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 24 (6) , 549-563
Bmal1 knockdown suppresses wake and increases immobility without altering orexin A, corticotrophin‐releasing hormone, or glutamate decarboxylase
Summary: Objective: To determine the effect of Bmal1 knockdown (KD) on sleep, activity, immobility, hypothalamic levels of orexin, corticotrophin‐releasing hormone (CRH), and GABAergic glutamate decarboxylase (GAD).Methods: We used Bmal1 siRNA, or control siRNA intracerebroventricular (ICV) injection to knock down Bmal1 in C57BL/6 mice. Sleep polysomnography, wheel‐running activity, and tail suspension test were performed. Polysomnographic (PSG) recordings in both groups were preceded by ICV injection made during both the light phase and the dark phase. We also measured brain orexin A and CRH using an ELISA and measured GAD using immunoblotting.Results: Compared with control group, Bmal1 KD group had reduced wheel activity and increased immobility. Compared with control, the Bmal1 KD group had reduced wheel activity and increased immobility. During the first 24 hours after treatment, we observed that control siRNA induced a much greater increase in sleep during the dark phase, which was associated with lower orexin levels. However, beginning 24 hours after treatment, we observed an increase in sleep and a decrease in time spent awake during the dark phase in the Bmal1 KD group. These changes were not associated with changes in brain levels of orexin A, CRH, or GAD.Conclusion: Bmal1 KD led to reduced activity, increased immobility, and dramatic reduction in time spent awake as well as an increase in sleep during the dark phase. Early after injection, there was a slight change in sleep but brain levels of orexin, CRH, and GAD remain unchanged. Control siRNA also affected sleep associated with changes in orexin levels.
- 14 February 2018
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 24 (6) , 549-563
Open AccessBmal1 knockdown suppresses wake and increases immobility without altering orexin A, corticotrophin‐releasing hormone, or glutamate decarboxylase
Summary: Objective: To determine the effect of Bmal1 knockdown (KD) on sleep, activity, immobility, hypothalamic levels of orexin, corticotrophin‐releasing hormone (CRH), and GABAergic glutamate decarboxylase (GAD).Methods: We used Bmal1 siRNA, or control siRNA intracerebroventricular (ICV) injection to knock down Bmal1 in C57BL/6 mice. Sleep polysomnography, wheel‐running activity, and tail suspension test were performed. Polysomnographic (PSG) recordings in both groups were preceded by ICV injection made during both the light phase and the dark phase. We also measured brain orexin A and CRH using an ELISA and measured GAD using immunoblotting.Results: Compared with control group, Bmal1 KD group had reduced wheel activity and increased immobility. Compared with control, the Bmal1 KD group had reduced wheel activity and increased immobility. During the first 24 hours after treatment, we observed that control siRNA induced a much greater increase in sleep during the dark phase, which was associated with lower orexin levels. However, beginning 24 hours after treatment, we observed an increase in sleep and a decrease in time spent awake during the dark phase in the Bmal1 KD group. These changes were not associated with changes in brain levels of orexin A, CRH, or GAD.Conclusion: Bmal1 KD led to reduced activity, increased immobility, and dramatic reduction in time spent awake as well as an increase in sleep during the dark phase. Early after injection, there was a slight change in sleep but brain levels of orexin, CRH, and GAD remain unchanged. Control siRNA also affected sleep associated with changes in orexin levels.
- 1 September 2016
- Published by Elsevier in Psychiatry Research
- Vol. 243, 210-218
Hippocampal and motor fronto-cortical neuroligin1 is increased in an animal model of depression
- 1 September 2016
- Published by Elsevier in Psychiatry Research
- Vol. 243, 210-218
Hippocampal and motor fronto-cortical neuroligin1 is increased in an animal model of depression
- 1 October 2015
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 69, 110-119
7,8-Dihydroxyflavone reduces sleep during dark phase and suppresses orexin A but not orexin B in mice
- 1 October 2015
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 69, 110-119
7,8-Dihydroxyflavone reduces sleep during dark phase and suppresses orexin A but not orexin B in mice
- 1 December 2014
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 59, 140-147
Chromosome 1 replacement increases brain orexins and antidepressive measures without increasing locomotor activity
- 1 December 2014
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 59, 140-147
Chromosome 1 replacement increases brain orexins and antidepressive measures without increasing locomotor activity
- 1 October 2012
- Published by Elsevier in Experimental Cell Research
- Vol. 318 (16) , 2004-2013
OX2R activation induces PKC-mediated ERK and CREB phosphorylation
- 1 October 2012
- Published by Elsevier in Experimental Cell Research
- Vol. 318 (16) , 2004-2013
OX2R activation induces PKC-mediated ERK and CREB phosphorylation
- 29 December 2011
- Published by Springer Nature in Sleep and Breathing
- Vol. 16 (4) , 1181-1191
Sleep-related epilepsy in a Long-Evans hooded rat model of depression
Introduction Neonatal treatment with clomipramine (CLI) has been shown to have reliable behavioral and biological changes that mimic major symptomatic and biochemical changes found in depression. This paper further explores a common feature of depression, the comorbidity of seizure activity and depressive behaviors in this mode. Methods Rat pups were neonatally treated with 40 mg/kg/day of CLI from postnatal day 8 through 21. In adulthood, they were instrumented with electroencephalographic (EEG) and electromyographic (EMG) electrodes for 24 h of polysomnogram (PSG) recordings. PSG data were analyzed for: (1) sleep-wake cycle; (2) spectral power; and (3) epileptiform activity, including NREM-to-REM transition (NRT) bursts. Results Neonatal treatment with CLI reliably produces enhanced levels of REM (p < 0.01) and reduced sexual activity (p < 0.05). Theta power was enhanced during NREM sleep in the CLI group (p = 0.02). CLI-treated animals experienced increased frequency at the NRT (p < 0.01), as well as additional epileptiform activity of continuous (CTS; p < 0.05) and petite-continuous (P-CTS; p < 0.01) types, across the sleep–wake cycle. There is a strong temporal correlation with increased REM sleep duration, increased frequency of NRT bursts, and increased theta power during NREM sleep in CLI-treated animals. Discussion Neonatal CLI-treated animals experienced significantly more epileptiform activity as a whole, in addition to comorbid features of depression in adulthood. Neonatal exposure to CLI will not only produce depressive phenotype but may also enhance risk for epilepsy in some individuals. This warrants further investigation into currently acceptable medicinal use in humans.
- 29 December 2011
- Published by Springer Nature in Sleep and Breathing
- Vol. 16 (4) , 1181-1191
Sleep-related epilepsy in a Long-Evans hooded rat model of depression
Introduction Neonatal treatment with clomipramine (CLI) has been shown to have reliable behavioral and biological changes that mimic major symptomatic and biochemical changes found in depression. This paper further explores a common feature of depression, the comorbidity of seizure activity and depressive behaviors in this mode. Methods Rat pups were neonatally treated with 40 mg/kg/day of CLI from postnatal day 8 through 21. In adulthood, they were instrumented with electroencephalographic (EEG) and electromyographic (EMG) electrodes for 24 h of polysomnogram (PSG) recordings. PSG data were analyzed for: (1) sleep-wake cycle; (2) spectral power; and (3) epileptiform activity, including NREM-to-REM transition (NRT) bursts. Results Neonatal treatment with CLI reliably produces enhanced levels of REM (p < 0.01) and reduced sexual activity (p < 0.05). Theta power was enhanced during NREM sleep in the CLI group (p = 0.02). CLI-treated animals experienced increased frequency at the NRT (p < 0.01), as well as additional epileptiform activity of continuous (CTS; p < 0.05) and petite-continuous (P-CTS; p < 0.01) types, across the sleep–wake cycle. There is a strong temporal correlation with increased REM sleep duration, increased frequency of NRT bursts, and increased theta power during NREM sleep in CLI-treated animals. Discussion Neonatal CLI-treated animals experienced significantly more epileptiform activity as a whole, in addition to comorbid features of depression in adulthood. Neonatal exposure to CLI will not only produce depressive phenotype but may also enhance risk for epilepsy in some individuals. This warrants further investigation into currently acceptable medicinal use in humans.
- 29 July 2011
- Published by Wiley in Developmental Neurobiology
- Vol. 72 (5) , 677-687
Maternal stress induces adult reduced REM sleep and melatonin level
We have previously reported that neonatal maternal deprivation (MD) resulted in a decrease of total sleep and an increase of orexin A in adult rats. Now, we characterized features of sleep, activity, and melatonin levels in rats neonatally treated with MD and control (MC) procedures. Adult male Sprague–Dawley rats were treated with either MD or MC procedures for 10 days starting at postnatal day 4. At 3 months of age, sleep was recorded for 48 h in one set of MD and MC rats, while another set of MD and MC rats was measured for locomotor activity (under LD = 12:12). Melatonin levels in the blood, pineal gland, and hypothalamus were measured as well as clock protein level in the hypothalamus. Compared to the MC rats, REM sleep in the MD rats was significantly reduced in the light periods but not in the dark periods. Both quiet wake and total wake in the MD rats were significantly increased during the light period compared to the MC rats. The weight of the pineal gland of the MD rats was significantly smaller than in MC rats. Melatonin levels of the MD group were significantly reduced in the pineal gland and hypothalamus compared to the MC group. No significant difference was identified between groups in the expression of the clock protein in the hypothalamus. Neonatal MD resulted in reduced REM sleep and melatonin levels, without changes of circadian cycle of locomotor activity and levels of clock protein. © 2011 Wiley Periodicals, Inc. Develop Neurobiol 72: 677–687, 2012
- 29 July 2011
- Published by Wiley in Developmental Neurobiology
- Vol. 72 (5) , 677-687
Maternal stress induces adult reduced REM sleep and melatonin level
We have previously reported that neonatal maternal deprivation (MD) resulted in a decrease of total sleep and an increase of orexin A in adult rats. Now, we characterized features of sleep, activity, and melatonin levels in rats neonatally treated with MD and control (MC) procedures. Adult male Sprague–Dawley rats were treated with either MD or MC procedures for 10 days starting at postnatal day 4. At 3 months of age, sleep was recorded for 48 h in one set of MD and MC rats, while another set of MD and MC rats was measured for locomotor activity (under LD = 12:12). Melatonin levels in the blood, pineal gland, and hypothalamus were measured as well as clock protein level in the hypothalamus. Compared to the MC rats, REM sleep in the MD rats was significantly reduced in the light periods but not in the dark periods. Both quiet wake and total wake in the MD rats were significantly increased during the light period compared to the MC rats. The weight of the pineal gland of the MD rats was significantly smaller than in MC rats. Melatonin levels of the MD group were significantly reduced in the pineal gland and hypothalamus compared to the MC group. No significant difference was identified between groups in the expression of the clock protein in the hypothalamus. Neonatal MD resulted in reduced REM sleep and melatonin levels, without changes of circadian cycle of locomotor activity and levels of clock protein. © 2011 Wiley Periodicals, Inc. Develop Neurobiol 72: 677–687, 2012
- Open Access
- 1 September 2001
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 24 (6) , 645-653
Ontogeny of REM Rebound in Postnatal Rats
The aim of this study was to determine developmental changes (ontogeny) of REM rebound in postnatal rats. Different groups of 2, 3, and 4-week-old experimental rats were instrumentally REM sleep deprived (RSD rats) for 33–48 hours and their sleep was monitored polysomnographically for 48 hours after the REM sleep deprivation (RSD). Age-matched control (RSC) rats also had polysomnographic recordings. N/A Subjects were 18 male Long-Evans RSD rats (5 age 2 weeks, 5 age 3 weeks, and 8 age 4 weeks); and 17 age-matched male Long Evans RSC rats (5 age 2 weeks, 5 age 3 weeks, and 7 age 4 weeks). Implants for the polysomnographic recordings of the RSD and RSC rats were made by the soft head plug method which permitted continuous, 24 hour/day records during the REM deprivation and post deprivation periods. RSD rats had instrumental RSD by the shaking platform method. RSC rats remained in stationary cages. At age 2 weeks, compared with age-matched RSC rats, RSD rats had no REM rebound. At age 3 weeks, compared with age-matched RSC rats, RSD rats had a small but significant REM rebound limited to the first 6 hours after RSD. At age 4 weeks, compared with RSC rats, RSD rats had a larger REM rebound that extended for 18 hours after RSD. The size and duration of REM rebound at the different ages was significantly different. Total sleep lost during the RSD process at each age was made up. The findings possibly indicate that in rats a REM sleep homeostatic process develops between ages 2 and 4 weeks and that a total sleep homeostatic process is already developed by age 2 weeks.
- 1 September 2001
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 24 (6) , 645-653
Open AccessOntogeny of REM Rebound in Postnatal Rats
The aim of this study was to determine developmental changes (ontogeny) of REM rebound in postnatal rats. Different groups of 2, 3, and 4-week-old experimental rats were instrumentally REM sleep deprived (RSD rats) for 33–48 hours and their sleep was monitored polysomnographically for 48 hours after the REM sleep deprivation (RSD). Age-matched control (RSC) rats also had polysomnographic recordings. N/A Subjects were 18 male Long-Evans RSD rats (5 age 2 weeks, 5 age 3 weeks, and 8 age 4 weeks); and 17 age-matched male Long Evans RSC rats (5 age 2 weeks, 5 age 3 weeks, and 7 age 4 weeks). Implants for the polysomnographic recordings of the RSD and RSC rats were made by the soft head plug method which permitted continuous, 24 hour/day records during the REM deprivation and post deprivation periods. RSD rats had instrumental RSD by the shaking platform method. RSC rats remained in stationary cages. At age 2 weeks, compared with age-matched RSC rats, RSD rats had no REM rebound. At age 3 weeks, compared with age-matched RSC rats, RSD rats had a small but significant REM rebound limited to the first 6 hours after RSD. At age 4 weeks, compared with RSC rats, RSD rats had a larger REM rebound that extended for 18 hours after RSD. The size and duration of REM rebound at the different ages was significantly different. Total sleep lost during the RSD process at each age was made up. The findings possibly indicate that in rats a REM sleep homeostatic process develops between ages 2 and 4 weeks and that a total sleep homeostatic process is already developed by age 2 weeks.
- Open Access
- 1 March 2000
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 23 (2) , 1-9
An Instrumental Method for Long-Term Continuous REM Sleep Deprivation of Neonatal Rats
The present study describes a new method for instrumental REM sleep deprivation (RSD) of neonatal rats. In the new method, an experimental neonatal rat and a yoked control neonatal rat were singly housed in a small plexiglass chamber which was divided into two separate units by a vertical wall. The floor of the housing chamber was attached to the platform of a standard laboratory test tube shaker. EEG and EMG electrodes were implanted by the soft head plug method which permitted continuous, long-term polysomnography. EEG and EMG signals were sent to a computer that was programmed to turn on the shaker for 5 seconds whenever the experimental rat entered REM sleep. NA NA NA The shaking of the chamber usually terminated REM sleep by entry to slow-wave sleep or wake. Amount of RSD depended on the shaker's oscillation speed. At higher speed the method reduced REM sleep by more than 80%. Thus, the new instrumental method of RSD can be used to study developmental functions of neonatal REM sleep. In particular, the instrumental method can test the hypothesis that in rats neonatal RSD produces the adult depressogenic effect of neonatally administered clomipramine.
- 1 March 2000
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 23 (2) , 1-9
Open AccessAn Instrumental Method for Long-Term Continuous REM Sleep Deprivation of Neonatal Rats
The present study describes a new method for instrumental REM sleep deprivation (RSD) of neonatal rats. In the new method, an experimental neonatal rat and a yoked control neonatal rat were singly housed in a small plexiglass chamber which was divided into two separate units by a vertical wall. The floor of the housing chamber was attached to the platform of a standard laboratory test tube shaker. EEG and EMG electrodes were implanted by the soft head plug method which permitted continuous, long-term polysomnography. EEG and EMG signals were sent to a computer that was programmed to turn on the shaker for 5 seconds whenever the experimental rat entered REM sleep. NA NA NA The shaking of the chamber usually terminated REM sleep by entry to slow-wave sleep or wake. Amount of RSD depended on the shaker's oscillation speed. At higher speed the method reduced REM sleep by more than 80%. Thus, the new instrumental method of RSD can be used to study developmental functions of neonatal REM sleep. In particular, the instrumental method can test the hypothesis that in rats neonatal RSD produces the adult depressogenic effect of neonatally administered clomipramine.